Longevity Health Holdings, Inc. (XAGE) stock
Close on Oct 19, 2026Market cap $277.24KP/E –Yield –
Longevity Health Holdings, Inc. grew revenue 60.3% to $1.69M over the twelve months to Jun 30, 2026. Free cash flow was -$3.34M. At the latest close the market valued the company at $277.24K.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $277.24K
- P/E ratio
- –
- Price to sales
- 0.16
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -1206.01%
Fundamentals
- Revenue
- $1.69M
- Net income
- -$6.83M
- EPS, diluted
- -$3.51
- Free cash flow
- -$3.34M
- Book value per share
- -$3.51
- Diluted shares
- 2M
Trading
- Previous close
- $0.11
- Open
- $0.11
- Day's range
- $0.11 – $0.11
- Volume
- 0
- Average volume (20 days)
- 5,996
Market cap history
Month-end market cap since 2023, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | XAGE | S&P 500 | Difference | XAGE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -34.1% | +0.6% | −34.7 pts | ||
| 3 months | -53.3% | +3.4% | −56.7 pts | ||
| Year to date | -62.8% | +13.3% | −76.1 pts | ||
| 1 year | -80.6% | +16.6% | −97.2 pts | ||
| 3 years | -99.9% | +86.4% | −186.2 pts | -88.8% | +23.1% |
| 5 years | -100.0% | +81.9% | −181.8 pts | -79.3% | +12.7% |
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Longevity Health filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- Update
- News
- News
- News
About Longevity Health
Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics
Longevity Health Holdings, Inc. develops and commercializes regenerative bio-aesthetic products focused on healthy aging, alongside a pipeline of bone and tissue healing technologies. The company operates in a single segment dedicated to these therapeutic and aesthetic categories. Its primary commercial offerings comprise two cosmetic lines, Elevai Exosomes and Carmell Secretome, which provide skincare and haircare solutions including post-treatment serums, daily aftercare lotions, cleansers, and scalp treatments. The company serves professional healthcare providers, such as dermatologists and plastic surgeons in medical spas and clinics, alongside retail consumers through online channels and distribution partners.
Company profile, executives and historyLongevity Health stock: common questions
What is Longevity Health's stock price?
XAGE closed at $0.11 on Oct 19, 2026, up 0.00% on the day.
What is Longevity Health's market cap?
Longevity Health was worth $277.24K at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is XAGE's P/E ratio?
Longevity Health lost money over the twelve months to Jun 30, 2026 (diluted EPS -$3.51), so it has no meaningful P/E ratio.
How much revenue does Longevity Health make?
Longevity Health reported revenue of $1.69M for the twelve months to Jun 30, 2026, up 60.3% from a year earlier.
Does Longevity Health pay a dividend?
No. Longevity Health has not paid a cash dividend over the last twelve months.
How has XAGE stock performed over the past year?
Including dividends, XAGE returned -80.6% over the past year, against +16.6% for the S&P 500.
Who are Longevity Health's competitors?
Companies most similar to Longevity Health by business, industry and size include BYAH, DQWS, WNW, SHFH, LGVN.
See a number that looks wrong?